Home
RNA Therapeutics USA

 

SAE Media Group’s inaugural Conference
RNA Therapeutics USA
14-15 June, 2023 | San Diego, CA, USA
-------------------------------------------------------------------------
SAE Media Group is proud to announce the inaugural RNA Therapeutics USA Conference taking place in San Diego on the 14 – 15th June 2023.

As part of SAE Media Group’s leading portfolio of Drug Discovery and the long-standing RNA Therapeutics Europe conferences, we are delighted to introduce RNA Therapeutics USA.

RNA therapies are leading the way in the field of genetic medicine, with the market expected to reach 1.81 billion USD by 2025, growing at a CAGR of 7.5%. This in large can be attributed to the topical advancements in mRNA vaccines, paving the way for global regulatory successes.

We currently see the RNA Therapeutic field focus on the challenges associated with delivery of RNA molecules extrahepatically, with a particular drive to overcome barriers of delivery to the Central Nervous System. In addition, RNA technologies continue to lead the way in revolutionising immunotherapies and the vaccine landscape, along with exceptional potential to treat a wide variety of chronic, previously undruggable diseases. The 2023 agenda will address these latest challenges along with recent advancements in RNAi and continue to drive innovation in the field of RNA Therapeutics.

Don't miss this opportunity to network with the pharma and biotech community of global experts in the UK and Europe; the two-day agenda offers you peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.

 

 

FEATURED SPEAKERS

Aditya Venkatesh

Aditya Venkatesh

Senior Principal Scientist, Stoke Therapeutics Inc
Anna Guzikowski

Anna Guzikowski

Scientist, Eclipsebio
Archit Rastogi

Archit Rastogi

Assistant Director, Ionis Pharmaceuticals
Chuong Huynh

Chuong Huynh

Biologist Officially / Vaccine Product Coordination Team Lead Unofficially, Biomedical Advanced Research & Development Authority (BARDA)
Heinrich Haas

Heinrich Haas

Former Vice President Formulation & Drug Delivery, BioNTech
Ho-Chou Tu

Ho-Chou Tu

Associate Director, Alnylam Pharmaceuticals
Jay Sarkar

Jay Sarkar

Researcher and Entrepreneur, Stanford University
Jimmy Weterings

Jimmy Weterings

Senior Director, Technology Innovation, Sirnaomics, Inc
Martin Akerman

Martin Akerman

CTO & Co-Founder, Envisagenics
Michael Ollmann

Michael Ollmann

Head of Oligonucleotide Biology, Janssen
Michelle Lynn-Hall

Michelle Lynn-Hall

Associate Vice President, Genetic Nanomedicine, Eli Lilly
Ramana Doppalapudi

Ramana Doppalapudi

Vice President, Chemistry, Avidity Biosciences
Ramana Doppalapudi

Ramana Doppalapudi

Vice President Chemistry, Avidity Biosciences Inc.
Stefano Zanotti

Stefano Zanotti

Senior Director, Head of Neuromuscular Research, Dyne Therapeutics
Steven Reed

Steven Reed

CEO, HDT Bio
Taishi Kimura

Taishi Kimura

Senior Scientist, HDT Bio
Ying Yu

Ying Yu

Associate Director, AbbVie

Aditya Venkatesh

Senior Principal Scientist, Stoke Therapeutics Inc
Aditya Venkatesh

Aditya Venkatesh combines over six years of experience in oligonucleotide therapeutics research with a strong background in retinal biology and ocular diseases. He is currently an Senior Principal Scientist at Stoke Therapeutics, where he has been involved in developing an antisense oligonucleotide-based approach to treat autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Prior to Stoke, he worked at Idera Pharmaceuticals validating an antisense oligonucleotide platform for rare disease targets. He received his Ph.D. in Biomedical Sciences from the laboratory of Claudio Punzo at UMass Chan Medical School. His doctoral work elucidated the role of the mTOR pathway in promoting cone photoreceptor cell survival and visual function in Retinitis Pigmentosa, a genetic disease that leads to blindness.

Anna Guzikowski

Scientist, Eclipsebio
Anna Guzikowski

Anna Guzikowski is a molecular biologist with over a decade of research experience in RNA biology. She specializes in protein translation and is currently a Scientist at Eclipsebio where she works to develop products that advance study of the translatome. Prior to joining Eclipse, she completed her PhD at UCSD where she studied the impact of acute glucose starvation stress on ribosome-mRNA interactions and protein synthesis.

Archit Rastogi

Assistant Director, Ionis Pharmaceuticals
Archit Rastogi

Christine Esau

Vice President, Arrowhead Pharmaceuticals
Christine Esau

Chuong Huynh

Biologist Officially / Vaccine Product Coordination Team Lead Unofficially, Biomedical Advanced Research & Development Authority (BARDA)
Chuong Huynh

Heinrich Haas

Former Vice President Formulation & Drug Delivery, BioNTech
Heinrich Haas

Heinrich has his professional focus on development of pharmaceutical products in the field of nanotechnology and drug & RNA delivery. In his Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz and academic career in Italy and Brazil he researched lipid membranes and organized bio-molecular systems. Having moved to pharmaceutical industry he developed nanoparticle products with application in cancer, inflammatory diseases autoimmune diseases and other indications. At BioNTech, he is the scientific lead of the formulation and analytics department, which develops RNA therapeutics based on a broad scope of delivery technologies..
 

Ho-Chou Tu

Associate Director, Alnylam Pharmaceuticals
Ho-Chou Tu

Ho-Chou Tu holds a PhD degree of Molecular and Cell biology from Washington University in St. Louis, she joined Alnylam Pharmaceuticals in 2015. She is currently leading a multidisciplinary team in discovery and translational research with the mission to identify novel RNAi targets for therapeutics to fuel and expand the future Alnylam pipeline. She is also leading the research effort in several early-mid clinical stage program teams, including hypertension, NASH and metabolic diseases.

Jay Sarkar

Researcher and Entrepreneur, Stanford University
Jay Sarkar

Dr. Sarkar is a researcher and entrepreneur with a background in applied physics and electrical engineering, which he utilizes to develop systems biology solutions for medicine. He built his first company off his foundational PhD work at Stanford University, where he pioneered the use the mRNA modality for transiently reprogramming cell epigenetics to specifically reset cellular age. The approach has grown as one of the hottest in the longevity community, with some of the largest startup investments in biotech history. He has now progressed to studying the broader problem of new modality integration and distribution in a variety of tissues.

Jimmy Weterings

Senior Director, Technology Innovation, Sirnaomics, Inc
Jimmy Weterings

Jim has had a tight bond with the development of Oligonucleotide Therapeutics since 2002, performing research on Peptide Nucleic Acid (PNA) in the van Boom group at Leiden University and targeted SSO conjugates at Prosensa. During his Ph.D at Leiden University, the Netherlands he generated and studied CpG Oligonucleotide and other Toll-like receptor targeting ligand containing conjugates. At Cenix BioScience, he developed siRNA conjugates for targeted CNS delivery. And at Cristal Therapeutics he led various projects on the nanomedicine delivery of oligonucleotide in oncology. In 2019, Jim joined AstraZeneca, Discovery Sciences in Sweden, to further advance the development of (targeted) oligonucleotide therapeutics. Recently Jim joined Sirnaomics, USA as Senior Director, Head of Technology Innovation with focus on again targeted delivery of oligonucleotides. Jimmy (co-)authored 13 articles and holds several patents for drug delivery enabling technologies, including the most recent one on TMTHSI, a superior conjugation compound to generate oligonucleotide and antibody conjugates. TMTHSI has recently been marketed as CliCr® with Iris Biotech and is licensed to Synaffix as well as part of a collaboration with Lonza.

Martin Akerman

CTO & Co-Founder, Envisagenics
Martin Akerman

Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.

Michael Ollmann

Head of Oligonucleotide Biology, Janssen
Michael Ollmann

Dr. Michael Ollmann is a Director and Head of Oligonucleotide Biology in the RNA Gene Therapy and Delivery group at Janssen, where he leads a group focused on in vitro and in vivo assays to support the discovery of nucleic acid therapeutics. Throughout his career, RNA interference (RNAi) has been a recurring theme, beginning with RNAi screens at Exelixis Inc. to discover drug targets and continuing at Amgen where he helped build the siRNA therapeutics platform. Mike obtained his Ph.D. in the lab of Dr. Greg Barsh at Stanford University.

Michelle Lynn-Hall

Associate Vice President, Genetic Nanomedicine, Eli Lilly
Michelle Lynn-Hall

Michelle Lynn Hall is currently the Senior Director of New Therapeutic Modalities at Eli Lilly, where she leads a team of engineers and scientists in the discovery of nucleic-acid-based therapies. Immediately prior to joining Lilly, Michelle worked at Moderna, where she led a team of modelers studying mRNA therapeutics design and lipid nanoparticle delivery. She received her Ph.D. from Columbia University where she developed a novel method to predict chemical reactivity and applied these to skills to a diverse set of problems ranging from materials science to biocatalysis. She then completed a joint postdoc at Novartis Institutes for Biomedical Research and Yale University, where she studied computer-aided drug design. She subsequently worked at Schrödinger where she focused on molecular simulations, machine learning, and chemical biology. She is passionate about equity, diversity, inclusion, and awareness in science, technology, engineering and math (STEM) and has served as a mentor, champion and advocate for women and minorities throughout her career. As a native Texan, she has intolerably strong opinions about BBQ.

Ramana Doppalapudi

Vice President Chemistry, Avidity Biosciences Inc.
Ramana Doppalapudi

Dr. Ramana Doppalapudi is a scientist with experience in the discovery and development of a variety of drugs including peptides, antibodies, oligonucleotides, and antibody drug conjugates. Over the last 23 years in the pharma and biotech industry, Dr. Doppalapudi developed multiple clinical candidates for the treatment of cancer, muscular diseases, and wet AMD. Dr. Doppalapudi is currently serving as Vice President, Chemistry at Avidity Biosciences in La Jolla, CA, USA where he is responsible for discovery chemistry and CMC.

Ramana Doppalapudi

Vice President, Chemistry, Avidity Biosciences
Ramana Doppalapudi

Dr. Ramana Doppalapudi is a scientist with experience in the discovery and development of a variety of drugs including peptides, antibodies, oligonucleotides, and antibody drug conjugates. Over the last 23 years in the pharma and biotech industry, Dr. Doppalapudi developed multiple clinical candidates for the treatment of cancer, muscular diseases, and wet AMD. Dr. Doppalapudi is currently serving as Vice President, Chemistry at Avidity Biosciences in La Jolla, CA, USA where he is responsible for discovery chemistry and CMC.

Samir Ounzain

CEO, HAYA Therapeutics
Samir Ounzain

Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the genome and its roles in development and disease. Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNAs CARMEN, Meteor and Wisper.

Stefano Zanotti

Senior Director, Head of Neuromuscular Research, Dyne Therapeutics
Stefano Zanotti

Stefano Zanotti is Head of Neuromuscular Research at Dyne Therapeutics, where he oversees preclinical development of treatments for genetically-driven muscular diseases. Stefano dedicated his career to rare genetic disorders. Prior to joining Dyne, Stefano led pre-clinical research programs in multiple rare diseases as Director of Rare Renal and Musculoskeletal Diseases at Sanofi. Previously, Stefano was an Assistant Professor at the UCONN School of Medicine, where he conducted NIH-funded research on genetic disorders of the skeletal system.
Stefano has authored more than 50 research articles and reviews in major scientific journals and received multiple awards for his contributions to skeletal biology.

Steven Reed

CEO, HDT Bio
Steven Reed

Steve Reed is the Founder, President, and CEO of the Infectious Disease Research Institute (IDRI), based in Seattle, USA. His academic appointments include Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington.

Dr. Reed’s dedication to global heath began during his undergraduate studies, and were the focus of this graduate studies at the University of Montana where he began work on adjuvants with Dr. Edgar Ribi. Dr. Reed received a PhD in Microbiology and Immunology from the University of Montana in 1979. That year he was appointed as Scientist of the National Institute of Amazon Research in Manaus, Brazil, where he directed research on tropical diseases.

Dr. Reed joined Cornell University Medical College in 1980 as Assistant Professor of Medicine, continuing to work in Brazil as manager of the Cornell-Bahia program in International Medicine. He joined the Seattle Biomedical Research Institute in 1984 where he worked until founding IDRI in 1993. He has received over $100 million in grants from the US NIH, BARDA, DARPA, and the Gates Foundation. In 1994 he co-founded Corixa Corporation (which was later sold to GlaxoSmithKline, GSK) where he served as Chief Scientific Officer until leaving in 2004. He also founded Dharma Therapeutics, a transdermal patch company, where he served as President from 2005-2008. In 2008 Dr. Reed, together with Rick Klausner, David Baltimore, and Ralph Steinman founded Immune Design Corp. (IMDZ, NASDAQ), a cancer therapeutics company, where he served as CEO until 2011.

Dr. Reed’s research interests have focused on the immunology of intracellular infections, and on the development of vaccines and diagnostics for both cancer and infectious diseases. In partnership with GSK, he led the team that developed the first defined tuberculosis vaccine, now in advanced clinical development. He also developed the first defined vaccines for leishmaniasis, as well as the K39-based diagnostic tests currently licensed for leishmaniasis. He has more than 350 original publications, 35 book chapters and reviews, and 105 issued patents on diagnostics, vaccines, and therapeutics of adjuvants, cancer, and infectious diseases.
 

Tae-Won Kim

Vice President, Preclinical Development, Ionis Pharmaceuticals
Tae-Won Kim

Taishi Kimura

Senior Scientist, HDT Bio
Taishi Kimura

I finished my PhD at Osaka University in Japan, focusing on the innate immune system against RNA viruses under the co-mentorship of Drs. Kiyoshi Takeda and Masahiro Yamamoto. I subsequently joined Dr. J. Lindsay Whitton's lab at Scripps Research Institute, where I led two viral myocarditis projects and secured an American Heart Association Postdoctoral Fellowship. At HDT Bio, I further developed my skills with training in RNA vaccinology. Currently, my research interest is to analyze how our vaccine platform (repRNA/LION) works and what’s the mechanism behind the high safety profile of this modality.

Ying Yu

Associate Director, AbbVie
Ying Yu


Over 25 years of research experiences in pharmaceutical companies and academic institutions with focus on RNA therapeutics, ophthalmic drug discovery and vascular physiology.

Expertise in small interference RNA (siRNA)-based drug target validation and RNA therapeutics. including 1) Selection of siRNAs lacking immunostimulatory properties; 2) in vivo siRNA-mediated cleavage assay development; 3) in vivo siRNA efficacy evaluation and 4) in vivo siRNA PK/PD assay development.
Two patents on novel gene discovery and siRNA delivery, awarded 4-year research grant from American heart association, two book chapters, several national awards, and over 30 papers in peer-reviewed journals including Nature, PNAS, Circulation and J Immunology.
 

sponsors

Conference agenda

clock

8:00

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Michelle Lynn-Hall, Associate Vice President, Genetic Nanomedicine, Eli Lilly

clock

9:10

Genetic (Nano)Medicine: State of the Art, Frontiers and Current Research

Michelle Lynn-Hall, Associate Vice President, Genetic Nanomedicine, Eli Lilly

  • Key challenges in genetic medicine
  • Case studies in nucleic acid API innovation
  • Case studies in delivery innovation
  • Future outlook
  • clock

    9:50

    An antisense oligonucleotide-based approach for the treatment of autosomal dominant optic atrophy

    Aditya Venkatesh, Senior Principal Scientist, Stoke Therapeutics Inc

  • Introduction to Stoke’s proprietary research platform TANGO
  • Application of TANGO for the treatment of autosomal dominant optic atrophy (ADOA)
  • Pre-clinical pharmacology data for STK-002, Stoke’s clinical candidate for ADOA
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    AI/ML developed RNA therapeutics for neurodegenerative diseases

    Martin Akerman, CTO & Co-Founder, Envisagenics

  • Overcoming in-silico modeling challenges for neurodegenerative diseases
  • How Envisagenics’ SpliceCore platform can be used in designing antisense oligonucleotides
  • Translational R&D from in-silico to in-vitro for potential ASO candidates in neurodegenerative disease
  • clock

    11:40

    The FORCETM platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy featuresin preclinical models

    Stefano Zanotti, Senior Director, Head of Neuromuscular Research, Dyne Therapeutics

  • Introduction to the FORCE platform
  • DYNE-101: application of the FORCE platform for the treatment of myotonic dystrophy type I
  • Insight into DYNE-101 delivery in NHP
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Targeted RNA therapeutics approaches for developing transformational medicines for patients

    Michael Ollmann, Head of Oligonucleotide Biology, Janssen

  •  RNA modalities for therapeutics and vaccine development
  • Novel carriers for improved extra-hepatic targeting
  • CNS delivery of siRNA for neurological disease therapies
  • clock

    14:00

    Utilizing eRibo products to interrogate ribosome RNA associations

    Anna Guzikowski, Scientist, Eclipsebio

  • Using sequencing technology to leverage a multidimensional view of transcripts from cap to tail
  • Introducing the eRibo family of products to provide comprehensive and accessible tools to study translation
  • How ribosome profiling technology can be used to gain insight into the translation status of a single transcript and the transcriptome
     
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Advancing RNA therapeutics through the development of long non-coding RNA therapies

    Samir Ounzain, CEO, HAYA Therapeutics

  •  Exploring new directions in the identifi cation of novel lncRNA targets
  • Reviewing antisense oligonucleotides in the targeting of disease generating lncRNAs
  • Case study: targeting the lncRNA Wisp
  • clock

    15:50

    Antibody Oligonucleotide Conjugates for the Treatment of Muscle Disorders

    Ramana Doppalapudi, Vice President, Chemistry, Avidity Biosciences

  • Challenges with oligonucleotide delivery
  • Development of antibody oligonucleotide conjugates (AOC) for the delivery of oligonucleotides
  • Application of AOC technology for the treatment of rare muscle genetic disorders
     
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day One

    Michelle Lynn-Hall, Associate Vice President, Genetic Nanomedicine, Eli Lilly

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Michelle Lynn-Hall, Associate Vice President, Genetic Nanomedicine, Eli Lilly

    clock

    9:10

    Utilising self-amplifying RNA technology

    Steven Reed, CEO, HDT Bio

  • Delving into model informed vaccine development for novel vaccines including self-amplifying RNA technology
  • Insight into HDT’s AMPLIFY vaccine platform which includes self-amplifying RNA
  • Enabling simplifi ed manufacturing processes, enhanced temperature stability and improved safety
  • Next steps: assessing the current fi eld and future work required or approval of novel vaccines
  • clock

    9:50

    Optimizing the safety of multivalent self amplifying replicon RNA vaccines

    Taishi Kimura, Senior Scientist, HDT Bio

  • We performed experiments in mice comparing the biodistribution and immune response after the vaccination with self-amplifying replicon RNA (repRNAs) formulated with LION (HDT's proprietary formulation) and LNP (a formulation widely used by others).
  • repRNA/LNP showed broad biodistribution, while repRNA/LION remained localized at the intramuscular site of administration.
  • repRNA/LNP induced both systemic and local innate responses, causing systemic inflammatory state and body weight loss, while repRNA/LION induced a robust local innate immune response without inducing systemic responses.
  • In the multivalent vaccine component, repRNA/LION induced better neutralizing antibody responses and protective immunity than repRNA/LNP.
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Accelerating the Development of Emerging Infectious Diseases: COVID Case study

    Chuong Huynh

    Chuong Huynh, Biologist Officially / Vaccine Product Coordination Team Lead Unofficially, Biomedical Advanced Research & Development Authority (BARDA)

  • Introduction to the BARDA’s vaccine strategy and approaches towards novel vaccines
  • Insight into BARDA’s COVID-19 Medical Countermeasure Portfolio
  • Strategies for developing successful COVID vaccine development contracts
  • clock

    11:40

    Panel Discussion: Reviewing RNA therapeutics as the next generation of genetic medicines

  • Discussing current drug like properties of RNA modalities
  • Advancing RNA medicines beyond current vaccine products
  • Dissecting the challenges associated with targeted delivery of RNA based therapies
  • Understanding the future direction of RNA based drugs, with a focus on emerging, novel RNA modalities
  • Tae-Won Kim

    Tae-Won Kim, Vice President, Preclinical Development, Ionis Pharmaceuticals

    Christine Esau

    Christine Esau, Vice President, Arrowhead Pharmaceuticals

    Archit Rastogi

    Archit Rastogi, Assistant Director, Ionis Pharmaceuticals

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Harnessing human genetics to target metabolic diseases with RNAi Therapeutics:

    Ho-Chou Tu, Associate Director, Alnylam Pharmaceuticals

  • RNAi therapeutics has demonstrated success in the clinic both in the rare and prevalent disease space
  • Human genetics is a powerful way to identify relevant drug targets with higher likelihood of success
  • Introducing early-stage GalNAc-siRNA programs targeting prevalent metabolic diseases (eg. T2D and NASH) based on human
  • clock

    14:00

    Developing siRNAs as the next generation of RNA therapies in Ocular Diseases

    Ying Yu, Associate Director, AbbVie

  • Establish siRNA-based target validation and therapeutic platform for ocular disease
  • Developing in vitro and in vivo assays that can effectively screen siRNAs lacking immunostimulatory properties.
  • Developing analytical approaches to study the pharmacokinetics of siRNA in the eye
  • A Case study: investigate the correlation between the pharmacokinetics and effi cacy of siRNA in rat retina
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    GalAhead™: a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes

    Jimmy Weterings, Senior Director, Technology Innovation, Sirnaomics, Inc

  • Introduction to GalAhead, Sirnaomics’ GalNAc-RNAi therapeutic platform
  • Validation of technology in vivo and in vitro
  • Progress report on GalAhead-based programs
  • clock

    15:50

    The Utility of RNA Cocktail Approaches and New Solutions for Combinational Therapy Distribution

    Jay Sarkar, Researcher and Entrepreneur, Stanford University

  • Combinational Logic In Gene Networks
  • Exploitation of these Networks using Exogenous RNA
  • Demonstrated Examples and Domain of Use Cases
  • Complexities of Cocktail Delivery and New Solutions to Accommodate
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day Two

    Michelle Lynn-Hall, Associate Vice President, Genetic Nanomedicine, Eli Lilly


    Senior Principal Scientist
    Stoke Therapeutics Inc
    Scientist
    Eclipsebio
    Assistant Director
    Ionis Pharmaceuticals
    Vice President
    Arrowhead Pharmaceuticals
    Biologist Officially / Vaccine Product Coordination Team Lead Unofficially
    Biomedical Advanced Research & Development Authority (BARDA)
    Former Vice President Formulation & Drug Delivery
    BioNTech
    Associate Director
    Alnylam Pharmaceuticals
    Researcher and Entrepreneur
    Stanford University
    Senior Director, Technology Innovation
    Sirnaomics, Inc
    CTO & Co-Founder
    Envisagenics
    Head of Oligonucleotide Biology
    Janssen
    Associate Vice President, Genetic Nanomedicine
    Eli Lilly
    Vice President Chemistry
    Avidity Biosciences Inc.
    Vice President, Chemistry
    Avidity Biosciences
    CEO
    HAYA Therapeutics
    Senior Director, Head of Neuromuscular Research
    Dyne Therapeutics
    CEO
    HDT Bio
    Vice President, Preclinical Development
    Ionis Pharmaceuticals
    Senior Scientist
    HDT Bio
    Associate Director
    AbbVie

    Sponsors

    Exhibitors

    Supporters

    Preliminary Attendee List

    Download

    Sponsors


    Eclipsebio

    Sponsors
    https://eclipsebio.com/?gclid=EAIaIQobChMI_pKAm9zi_AIVkr7tCh0gSQOREAAYASAAEgKL5PD_BwE

    Eclipsebio has developed multiple world-class RNA genomics products used by biopharma and academic customers around the world to accelerate the development of tomorrow’s key RNA genomics discoveries and medicines.

    Our innovative standard and customizable solutions bring new and deeper insights to the RNA interactome by providing more accurate, reproducible and useable data for our customers.

    Our products:

    - Identify new RNA regulatory and epigenetic mechanisms

    - Spur exciting new insights into mRNA

    - RNA binding protein and miRNA biology

    - Map new RNA drug targets to accelerate the development of safe and effective RNA medicines


    Exhibitors


    ChemGenes

    Exhibitors
    http://www.chemgenes.com

    ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.


    Lexogen

    Exhibitors
    https://www.lexogen.com/

    Established in 2007, Lexogen is a global leading company in transcriptomics, next-generation sequencing, RNA analysis and bioinformatics. Our mission is to empower our customers with innovative top quality RNA analysis solutions & support, in order to improve health and well-being for everyone and our planet. Lexogen, an ISO 9001 certified company, is the leader in 3’ mRNA sequencing, a technology proven for its efficiency, its robustness, and its sensitivity.

    Lexogen’s portfolio includes innovative kits developed and produced in Vienna, Austria for:

    • true single-cell as well as bulk RNA sequencing,

    • RNA extraction,

    • RNA extraction,

    • spike-in RNA variant controls, and

    • nascent RNA labeling for transcriptome-wide analysis of RNA kinetics.

    Lexogen also provides first-class, fully integrated, customizable RNA sequencing services, from experimental design consulting to sample processing and tailored bioinformatics analytical reporting.

    Lexogen is a privately held company headquartered in Vienna, Austria, with a subsidiary in New Hampshire, USA.


    Media Partners


    1STRAND

    Supporters
    https://1strand.org/

    Founded in 2020, 1STRAND sets to showcase San Diego County as the premier location for RNA therapeutics R&D, provide a forum to highlight the positive impact of RNA medicines on public health, and to connect professionals in the space and grow the local talent pool of qualified individuals.


    Horton Grand Hotel


    USA

    Horton Grand Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.